News
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
Stocktwits on MSN1h
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays DullRegeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...
IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...
Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...
Further expanding the indications for French pharma major Sanofi’s (Euronext: SAN) mega-blockbuster Dupixent (dupilumab), the ...
Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and ...
And more pharma news updates from Pharmalittle.
Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...
His diet used to come in a juice box. Now, at 24, he’s learning how to eat, taste, and enjoy food for the first time — on ...
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid <li /> Approval based on pivotal re ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback